New hope for celiac sufferers: drug targets stubborn symptoms

NCT ID NCT04424927

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called PRV-015 in 388 adults with celiac disease who still had symptoms like belly pain and bloating even after following a strict gluten-free diet. The goal was to see if the drug could reduce these symptoms better than a placebo. Participants took the drug or a placebo for 24 weeks while continuing their gluten-free diet.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease refractory celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Site

    Los Angeles, California, 90036, United States

  • Clinical Site

    Ventura, California, 93003, United States

  • Clinical Site

    Denver, Colorado, 80209, United States

  • Clinical Site

    Leesburg, Florida, 34748, United States

  • Clinical Site

    Tampa, Florida, 33613, United States

  • Clinical Site

    Winter Park, Florida, 32789, United States

  • Clinical Site

    Chicago, Illinois, 60637, United States

  • Clinical Site

    Boston, Massachusetts, 02111, United States

  • Clinical Site

    Chesterfield, Michigan, 48047, United States

  • Clinical Site

    Rochester, Minnesota, 55905, United States

  • Clinical Site

    Morristown, New Jersey, 07960, United States

  • Clinical Site

    New Windsor, New York, 12553, United States

  • Clinical Site

    Raleigh, North Carolina, 27607, United States

  • Clinical Site

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Site

    Uniontown, Pennsylvania, 14401, United States

  • Clinical Site

    Warwick, Rhode Island, 02886, United States

  • Clinical Site

    Nashville, Tennessee, 37212, United States

  • Clinical Site

    Garland, Texas, 75044, United States

  • Clinical Site

    West Jordan, Utah, 84088, United States

  • Clinical Site

    Bellevue, Washington, 98004, United States

  • Clinical Site

    Tacoma, Washington, 98405, United States

  • Clinical Site

    Hamilton, Ontario, L8S4K1, Canada

  • Clinical Site

    Amsterdam, 1105 AZ, Netherlands

  • Clinical Site

    Seville, Andalusia, 41013, Spain

  • Clinical Site

    León, Castille and León, 24071, Spain

  • Clinical Site

    Madrid, 28034, Spain

  • Clinical Site

    Madrid, 28041, Spain

  • Clinical Site

    Madrid, 28222, Spain

  • Clinical Trial Site

    Northbrook, Illinois, 60062, United States

  • Clinical Trial Site

    Chevy Chase, Maryland, 20815, United States

  • Clinical Trial Site

    Brooklyn, New York, 11235, United States

  • Clinical Trial Site

    New York, New York, 10032, United States

  • Clinical Trial Site

    Dublin, Ohio, 43016, United States

  • Clinical Trial Site

    North Charleston, South Carolina, 29405, United States

  • Clinical Trial Site

    Cedar Park, Texas, 78613, United States

  • Clinical Trial Site

    Terrassa, Catalonia, 082211, Spain

  • Clinical Trial Site

    Girona, 17007, Spain

  • Clinical Trial Site

    Lleida, 25196, Spain